Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-β-d-ribofuranosyl) pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7808-7820

  Bookser, Brett C ^a   Ugarkar, Bheemarao G ^a   Matelich, Michael C ^a   Lemus, Robert H ^a   Allan, Matthew ^a   Tsuchiya, Megumi ^b   Nakane, Masami ^b   Nagahisa, Atsushi ^b   Wiesner, James B ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (PHENYLAMINO) 5 PHENYL 7 (5 DEOXY BETA DEXTRO RIBOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE; 4 N (N CYCLOPROPYLCARBAMOYLMETHYL)AMINO 5 PHENYL 7 (5 DEOXY BETA DEXTRO RIBOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE; ADENOSINE KINASE INHIBITOR; BRADYKININ; GP 3269; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; ATAXIA; CONTROLLED STUDY; CRYSTALLIZATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; MARMOSET; NONHUMAN; RAT; SEDATION; SOLID STATE; STRUCTURE ACTIVITY RELATION; VOMITING;

ADENOSINE KINASE; ANALGESICS; ANIMALS; BIOLOGICAL AVAILABILITY; CALLITHRIX; DOGS; DRUG STABILITY; GLYCINE; HUMANS; MALE; MICROSOMES, LIVER; NUCLEOSIDES; PAIN MEASUREMENT; PYRIMIDINE NUCLEOSIDES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 28144445057     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050394a     Document Type: Article

References (59)

1. (a) Ugarkar, B. G.; DaRe, J. M.; Kopcho, J. J.; Browne, C. E. III; Schanzer, J. M.; Wiesner, J. B.; Erion, M. D. Adenosine Kinase Inhibitors. 1. Synthesis, Enzyme Inhibition and Anti-seizure Activity of 5-Iodotubercidin Analogues. J. Med. Chem. 2000, 43, 2883-2893.
2. (b) Ugarkar, B. G.; Castellino, A. J.; DaRe, J. M.; Kopcho, J. J.; Wiesner, J. B.; Schanzer, J. M.; Erion, M. D. Adenosine Kinase Inhibitors. 2. Synthesis, Enzyme Inhibition and Antiseizure Activity of Diaryltubercidin Analogues. J. Med. Chem. 2000, 43, 2894-2905.
3. Erion, M. D.; Ugarkar, B. G.; DaRe, J.; Castellino, A. J.; Fujitaki, J. M.; Dixon, R.; Appleman, J. R.; Wiesner, J. B. Design, Synthesis and Anticonvulsant Activity of the Potent Adenosine Kinase Inhibitor GP2639. Nucleosides, Nucleotides Nucleic Acids 1997, 16, 1013-1021.
4. Weisner, J. B.; Ugarkar, B. G.; Castellino, A. J.; Barankiewicz, J.; Dumas, D. P.; Gruber, H. E.; Foster, A. C.; Erion, M. D. Adenosine Kinase Inhibitors as a Novel Approach to Anticonvulsant Therapy. J. Pharmacol. Exp. Ther. 1999, 289, 1669-1677.
5. (e) Pak, M. A.; Hass, H. L.; Decking, U. K. M.; Schrader, J. Inhibition of Adenosine Kinase Increases Endogenous Adenosine and Depresses Neuronal Activity in Hippocampal Slices. Neuropharmacology 1994, 33, 1049-1053.
6. Tatlisumak, T.; Takano, K.; Carano, R.; Miller, L. P.; Foster, A. C.; Fisher, M. Delayed Treatment with an Adenosine Kinase Inhibitor, GP683, Attenuates Infarct Size in Rats with Temporary Middle Cerebral Artery Occlusion. Stroke 1998, 29, 1952-1958.
7. (a) Ugarkar, B. G.; Castellino, A. J.; DaRe, J. S.; Ramirez-Weinhouse, M.; Kopcho, J. J.; Rosengren, S.; Erion, M. D. Adenosine Kinase Inhibitors. 3. Synthesis, SAR and Antiinflammatory Activity of a Series of L-Lyxofuranosyl Nucleosides. J. Med. Chem. 2003, 46, 4750-4760.
8. (b) Firestein, G. S.; Boyle, D.; Bullough, D. A.; Gruber, H. E.; Sajjadi, F. G.; Montag, A.; Sambol, B.; Mullane, K. M. Protective effect of an adenosine kinase inhibitor in septic shock. J. Immunol. 1994, 152, 5853-5859.
9. Firestein, G. S.; Bullough, D. A.; Erion, M. D.; Jimenez, R.; Ramirez-Weinhouse, M.; Barankiewicz, J.; Smith, C. W.; Gruber, H. E.; Mullane, K. M. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor: The role of selectins. J. Immunol. 1995, 154, 326-334.
10. Villarreal, F.; Zimmermann, S.; Makhsudova, L.; Montag, A. C.; Erion, M. D.; Bullough, D. A.; Ito, B. R. Modulation of cardiac remodeling by adenosine: In vitro and in vivo effects. Mol. Cell. Biochem. 2003, 251, 17-26.
11. (a) Keil II, G. J.; DeLander, G. E. Adenosine kinase and adenosine deaminase inhibition modulate spinal adenosine- and opiod agonist-induced antinociception in mice. Eur. J. Pharmacol. 1994, 271, 37-46.
12. (b) Sawynok, J.; Liu, X. J. Adenosine in the spinal cord and periphery: Release and regulation of pain. Prog. Neurobiol. 2003, 69, 313-340.
13. (a) Boyer, S. H.; Ugarkar, B. G.; Solbach, J.; Kopcho, J.; Matelich, M. C.; Ollis, K.; Gomez-Galeno, J. E.; Mendonca, R.; Tsuchiya, M.; Nagahisa, A.; Nakane, M.; Wiesner, J. B.; Erion, M. D. Adenosine Kinase Inhibitors. 5. Synthesis, Enzyme Inhibition and Analgesic Activity of Erythro Diarylturbercidin Analogs. J. Med. Chem. 2005, 48, 6430-6441.
14. (b) Preliminary report: Ugarkar, B. G.; Lemus, R. H.; Gomez-Galeno J. E.; Matelich, M. C.; Boyer, S. H.; Wiesner, J. B.; Booten, S.; Erion, M. D.; Tsuchiya, M.; Nakane, M.; Nagahisa, A. Adenosine Kinase Inhibitors 1. A New Class of Potential Analgesic Agents. Abstr. Pap.-Am. Chem. Soc. 2001, 221, CARB-032.
15. Jarvis, M. F.; Yu, H. X.; Kohlhaas, K.; Alexander, K.; Lee, C. H.; Jiang, M. Q.; Bhagwat, S. S.; Williams, M.; Kowaluk, E. A. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J. Pharmacol. Exp. Ther. 2000, 295, 1156-1164.
16. Kowaluk, E. A.; Mikusa, J.; Wismer, C. T.; Zhu, C. Z.; Schweitzer, E.; Lynch, J. J.; Lee, C. H.; Jiang, M. Q.; Bhagwat, S. S.; Gomtsyan, A.; McKie, J.; Cox, B. F.; Polakowski, J.; Reinhart, G.; Williams, M.; Jarvis, M. F. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, a novel orally effective adenosine kinase inhibitor with analgesic and antiinflammatory properties: I. In vivo characterization in the rat. J. Pharmacol. Exp. Ther. 2000, 295, 1165-1174.
17. (a) Jacobson, K. A.; van Galen, P. J. M.; Williams, M. Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential. J. Med. Chem. 1992, 35, 407-422.
18. (b) Erion, M. D. Adenosine Receptors as Pharmacological Targets. Annu. Rep. Med. Chem. 1993, 28, 295-304.
19. Purinergic Approaches in Experimental Therapeutics; Jacobson, K. A., Jarvis, M. F., Eds.; Wiley-Liss: New York, 1997.
20. Williams, M.; Jarvis, M. F. Purinergic and pyrimidinergic receptors as potential drug targets. Biochem. Pharmacol. 2000, 59, 1173-1185.
21. (a) Bookser, B. C.; Matelich, M. C.; Ollis, K.; Ugarkar, B. G. Adenosine Kinase Inhibitors. 4. 6,8-Disubstituted Purine Nucleoside Derivatives. Synthesis, Conformation, and Enzyme Inhibition. J. Med. Chem. 2005, 48, 3389-3399.
22. (b) Another approach to ARAs is by inhibition of AMP deaminase. See for example: Erion, M. D.; Kasibhatla, S. R.; Bookser, B. C.; van Poelje, P. D.; Reddy, M. R.; Gruber, H. E.; Appleman, J. R. Discovery of AMP Mimetics that Exhibit High Inhibitory Potency and Specificity for AMP Deaminase. J. Am. Chem. Soc. 1999, 121, 308-319.
23. Dubuisson, D.; Dennis, S. G. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brainstem stimulation in rats and cats. Pain 1977, 4, 161-164.
24. Woolfe, G.; MacDonald, A. D. The evaluation of the analgesic action of pethidine hydrochloride (demeral) J. Pharmacol. Exp. Ther. 1944, 80, 300-307.
25. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 1941, 72, 74-79.
26. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-23.
27. (a) Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today 1998, 1, 387-393.
28. (b) Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
29. (a) Gewald, K. Reaktion von Malonsauredinitril mit α-Aminoketonen. Z. Chem. 1961, 1, 349.
30. (b) Abdalla, G. M.; Sowell, J. W. Sr. Synthesis of 8-Cyano-1,4-dihydro-4- oxopyrrolo[1,2-a]pyrimidine-3-carboxylic Acids as Potential Antimicrobial Agents. J. Heterocycl. Chem. 1987, 24, 297-301.
31. Wilcox, C. S.; Otoski, R. M. Stereoselective Preparations of Ribofuranosyl Chlorides and Acetates. Solvent Effects and Stereoselectivity in the Reaction of Ribofuranosyl Acetates with Trimethylallylsilane. Tetrahedron Lett. 1986, 27, 1011-1014.
32. 4 Dimethyl Ester. J. Am. Chem. Soc. 1983, 105, 3661-3672.
33. Use of the Vilsmeyer salt to prepare chloro sugars will be reported in detail elsewhere: Kopcho, J.; Ugarkar, B. G. Unpublished research.
34. Wang, G.; Ta, R. C.; Gunic, E.; Du, J.; Bard, J.; Pai, B. Synthesis and Cytokine Modulation Properties of Pyrrolo[2,3-d]-4-pyrimidone Nucleosides. J. Med. Chem. 2000, 43, 2566-2574.
35. The synthesis of amino acid substituted nucleosides has precedent going back to the pioneering work of Carter and others: (a) Carter, C. E. Synthesis of 6-Succinioaminopurine. J. Biol. Chem. 1956, 223, 139-146.
36. (b) Ward, D. N.; Wade, J.; Walborg, E. F. Jr.; Osdene, T. S. The Synthesis of N-(6-Purinyl)amino Acids. Amino Acids with a Single Reactive Amino Group. J. Org. Chem. 1961, 26, 5000-5005.
37. Vickers, R. S.; Gerster, J. F.; Robins, R. K. N-(2-Amino-9-β-D- ribofuranosyl-9H-purin-6-yl)-glycine. Preparation of a Nucleoside Derivative of an Amino Acid in Synthetic Procedures in Nucleic Acid Chemistry; Zorbach, W. W.; Tipson, R. S.; Eds.; John Wiley and Sons: New York, 1968; pp. 281-282, Chapter 90.
38. (a) Taylor, E. C.; Hendess, R. W. Synthesis of Pyrrolo[2,3-d]- pyrimidines. The Aglycon of Toyocamycin. J. Am. Chem. Soc. 1965, 87, 1995-2003.
39. (b) Widler, L.; Green, J.; Missbach, M.; Susa, M.; Altmann, Eva 7-Alkyl- and 7-Cycloalkyl-5-aryl-pyrrolo-[2,3-d]pyrimidines-Potent Inhibitors of the Tyrosine Kinase c-Src. Bioorg. Med. Chem. Lett. 2001, 11, 849-852.
40. Cottam, H. B.; Petrie, C. R.; McKernan, P. A.; Goebel, R. J.; Dalley, N. K.; Davidson, R. B.; Robins, R. K.; Revankar, G. R. Synthesis and Biological Activity of Certain 3,4-Disubstituted Pyrazolo[3,4-d]pyrimidine Nucleosides. J. Med. Chem. 1984, 27, 1119-1127.
41. (a) Kobayashi, S. The Synthesis and Xanthine Oxidase Inhibitory Activity of Pyrazolo[3,4-d]pyrimidines. Chem. Pharm. Bull. 1973, 21, 941-951.
42. (b) Tominaga, Y.; Matsuoka, Y.; Oniyama, Y.; Uchimura, Y.; Komiya, H.; Hirayama, M.; Kohra, S.; Hosomi, A. Polarized Ethylenes. IV [1]. Synthesis of Polarized Ethylenes Using Thioamides and Methyl Dithiocarboxylates and Their Application to the Syntheses of Pyrazoles, Pyrimidines, Pyrazolo-[3,4-d] pyrimidines and 5-Aza[2.2.3]cyclazines. J. Heterocycl. Chem. 1990, 27, 647-660.
43. Kraybill, B. C.; Elkin, L. L.; Blethrow, J. D.; Morgan, D. O.; Shokat, K. M. Inhibitor Scaffolds as New Allele Specific Kinase Substrates. J. Am. Chem. Soc. 2002, 124, 12118-12128.
44. Browne, C. E.; Ugarkar, B. G.; Mullane, K. M.; Gruber, H. E.; Bullough, D. A.; Erion, M. D.; Castellino, A. J. Adenosine Kinase Inhibitors. U.S. Patent No. 5,864,033, January 1999.
45. (a) Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95, 2457-2483.
46. (b) Suzuki, A. In Metal-Catalyzed Cross-Coupling Reactions; Diederich, F., Stang, P. J., Eds.; Wiley-VCH: Weinheim, Germany, 1998; Chapter 2.
47. (a) Basha, A.; Lipton, M.; Weinreb, S. M. A Mild, General Method for Conversion of Esters to Amides. Tetrahedron Lett. 1977, 4171-4174.
48. (b) Levin, J. I.; Turos, E.; Weinreb, S. M. An Alternative Procedure for the Aluminum-Mediated Conversion of Esters to Amides. Synth. Commun. 1982, 12, 989-993.
49. Lipton, M. F.; Basha, A.; Weinreb, S. M. Conversion of Esters to Amides with Dimethylaluminum Amides: N,N-Dimethylcyclohexanecarboxamide. Org. Synth. 1979, 59, 49-53.
50. (a) Scheibye, S.; Pedersen, B. S.; Lawesson, S.-O. Studies on Organophosphorous Compounds XXI. The Dimer of 2-Methoxyphenylthionophosphine Sulfide as Thiation Reagent. A New Route to Thiocarboxamides. Bull. Soc. Chim. Belg. 1978, 87, 229-238.
51. (b) For a review of the Lawesson's reagent see Cava, M. P.; Levinson, M. I. Thionation Reactions of Lawesson's Reagents. Tetrahedron 1985, 41, 5061-5087.
52. Additional modified sugar and pyrazolopyrimidine diaryltubercidine analogues: Ugarkar, B. G.; Matelich, M. C.; Boyer, S. Unpublished research.
53. Randal, L. O.; Selito, J. J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. 1957, 111, 409-419.
54. The use of bradykinin is a modification of a known procedure employing formalin: Alreja, M.; Mutalik, P.; Mayar, U.; Manchanda, S. K. The formalin test: A tonic pain model in the primate. Pain 1984, 20, 97-105.
55. (a) Mathews, I. I.; Erion, M. D.; Ealick, S. E. Structure of Human Adenosine Kinase at 1.5 Å Resolution. Biochemistry 1998, 37, 15607-15620.
56. (b) Schumacher, M. A.; Scott, D. M.; Mathews, I. I.; Ealick, S. E.; Roos, D. S.; Ullman, B.; Brennan, R. G. Crystal Structures of Toxoplasma gondii Adenosine Kinase Reveal a Novel Catalytic Mechanism and Prodrug Binding. J. Mol. Biol. 2000, 296, 549-567.
57. Cook, W. J.; DeLucas, L. J.; Chattopadhyay, D. Crystal structure of adenosine kinase from Toxoplasma gondii at 1.8 Å resolution. Protein Sci. 2000, 9, 704-712.
58. (a) Ojima, H.; Yamada, K. Synthesis and Characterization of μ-bis[N-(hydroxypropyl)glycinamidato(2-)]dicopper(II) and μ-bis-[N-(hydroxypropyl)-DL-alaninamidato(2-)]dicopper(II). Z. Anorg. Allg. Chem. 1970, 379, 322-8.
59. (b) Angrick, M.; Rewicki, D. Reactions of Sugars and Related Polyfunctional Compounds with Amino Acids. 2. N-Acylation of 3-Amino-1,2-propanediol with Amino Acids. Liebigs Ann. Chem. 1982, 1394-1397.